3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Pleural Effusion, Malignant
4
Breast Neoplasms
4
Immunoglobulin Light-chain Amyloidosis
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Non-Hodgkin
2
Exanthema
2
Amyloidosis
2
Waldenstrom Macroglobulinemia
1
Urologic Neoplasms
1
Tuberous Sclerosis
1
Triple Negative Breast Neoplasms
1
Tissue Adhesions
1
Skin Toxicity
1
Sezary Syndrome
1
Ras-wildtype Colorectal Cancer
1
Polyps
1
Polycystic Ovary Syndrome
1
Pain
1
Ovarian Neoplasms
1
Neurofibromatosis 2
1
Neoplasms, Second Primary
1
Neoplasms
1
Myoma
1
Menstruation Disturbances
1
Melanoma
1
Interventions
Paclitaxel
326
Carboplatin
318
Bevacizumab
167
Gemcitabine
106
pembrolizumab
101
liposomal doxorubicin
100
Cyclophosphamide
96
Topotecan
93
Cisplatin
89
olaparib
86
niraparib
60
Docetaxel
56
Taxes
52
Doxorubicin
50
Drug Therapy
42
fludarabine
40
Filgrastim
39
Nivolumab
37
Etoposide
32
Specimen Handling
31
Magnetic Resonance Spectroscopy
29
Immunoglobulin G
27
Disulfides
27
Peripheral Blood Stem Cell Transplantation
26
Albumin-Bound Paclitaxel
25
durvalumab
24
aldesleukin
24
Hyperthermic Intraperitoneal Chemotherapy
24
Oxaliplatin
23
Biopsy
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Ovarian Neoplasms
×
Doxycycline
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn